TABLE 1.
Participant demographics and baseline characteristics
| Characteristics | TX-004HR 4 μg (n = 18) | TX-004HR 10 μg (n = 19) | TX-004HR 25 μg (n = 18) | Placebo (n = 17) |
| Age, y | 57.4 ± 7.1 | 58.5 ± 7.1 | 59.2 ± 6.4 | 58.9 ± 6.1 |
| Race, n (%) | ||||
| White | 18 (100) | 18 (94.7) | 16 (88.9) | 16 (94.1) |
| Black or African American | 0 (0) | 1 (5.3) | 2 (11.1) | 1 (5.9) |
| BMI, kg/m2 | 28.3 ± 5.6 | 28.2 ± 4.5 | 28.9 ± 5.3 | 27.2 ± 5.5 |
| Smoking history, n (%) | ||||
| No | 12 (66.7) | 6 (31.6) | 12 (66.7) | 10 (58.8) |
| Yes | 6 (33.3) | 13 (68.4) | 6 (33.3) | 7 (41.2) |
| Years of smoking | 33.2 ± 12.0 | 21.8 ± 11.2 | 23.8 ± 15.8 | 21.9 ± 12.4 |
| Baseline hormone values, pg/mL | ||||
| Estradiol | 3.9 ± 2.4 | 4.9 ± 3.4 | 3.6 ± 1.7 | 4.5 ± 2.6 |
| Estrone | 15.3 ± 4.8 | 20.3 ± 8.6 | 16.7 ± 7.8 | 19.4 ± 8.8 |
| Estrone conjugates | 237.7 ± 180.8 | 239.2 ± 174.2 | 343.4 ± 421.1 | 275.9 ± 152.6 |
Data represented as mean ± SD unless stated otherwise.
BMI, body mass index.